Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients

Initially, acute loss of smell (anosmia) and taste (ageusia) was not considered important symptoms for coronavirus disease 2019 (COVID-19). To determine the prevalence of these symptoms and to evaluate their diagnostic significance, we (approximately 150 physicians of the Daegu Medical Association)...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of Korean medical science Ročník 35; číslo 18; s. e174 - 6
Hlavní autori: Lee, Yonghyun, Min, Pokkee, Lee, Seonggu, Kim, Shin-Woo
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Korea (South) The Korean Academy of Medical Sciences 11.05.2020
대한의학회
Predmet:
Adult
Age Distribution
Ageusia - epidemiology
Ageusia - etiology
Betacoronavirus
Brief Communication
Clinical Laboratory Techniques
Coronavirus - genetics
Coronavirus - isolation & purification
Coronavirus Infections - complications
Coronavirus Infections - diagnosis
Coronavirus Infections - epidemiology
COVID-19
COVID-19 Testing
Female
Humans
Male
Olfaction Disorders - epidemiology
Olfaction Disorders - etiology
Pandemics
Pneumonia, Viral - complications
Pneumonia, Viral - epidemiology
Polymerase Chain Reaction
Prevalence
Republic of Korea - epidemiology
SARS-CoV-2
Sex Distribution
Smell
Taste
의학일반
Republic of Korea
COVID-19
Loss of Taste
Anosmia
Ageusia
Loss of Smell
ISSN:1011-8934, 1598-6357, 1598-6357
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Initially, acute loss of smell (anosmia) and taste (ageusia) was not considered important symptoms for coronavirus disease 2019 (COVID-19). To determine the prevalence of these symptoms and to evaluate their diagnostic significance, we (approximately 150 physicians of the Daegu Medical Association) prospectively collected data of cases of anosmia and ageusia from March 8, 2020, via telephone interview among 3,191 patients in Daegu, Korea. Acute anosmia or ageusia was observed in 15.3% (488/3,191) patients in the early stage of COVID-19 and in 15.7% (367/2,342) patients with asymptomatic-to-mild disease severity. Their prevalence was significantly more common among females and younger individuals ( = 0.01 and < 0.001, respectively). Most patients with anosmia or ageusia recovered within 3 weeks. The median time to recovery was 7 days for both symptoms. Anosmia and ageusia seem to be part of important symptoms and clues for the diagnosis of COVID-19, particularly in the early stage of the disease.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
https://jkms.org/search.php?where=aview&id=10.3346/jkms.2020.35.e174&code=0063JKMS&vmode=FULL
ISSN:1011-8934
1598-6357
1598-6357
DOI:10.3346/jkms.2020.35.e174